Similarly, a recent study demonstrated that endogenous AKAP1 was reduced in primary neurons treated with Aβ42 peptide in vitro and in the hippocampus and cortex of asymptomatic and symptomatic AD animals in vivo [98]. The gene discussed is AKAP1; the disease is Alzheimer disease.